2021 年第 6 期 第 16 卷

安罗替尼联合注射用紫杉醇（白蛋白结合型）二线治疗晚期驱动基因阴性非小细胞肺癌的效果及安全性分析

Therapeutic effect and safety of second-line treatment of anlotinib combined with paclitaxel for injection (albumin bound) on advanced driving gene negative non-small cell lung cancer

作者：徐珊珊1施朕善1王强强1兰峰1苏方2

英文作者：Xu Shanshan1 Shi Zhenshan1 Wang Qiangqiang1 Lan Feng1 Su Fang2

单位：1安徽省亳州市人民医院肿瘤科236800；2蚌埠医学院第一附属医院肿瘤内科233004

英文单位：

关键词：非小细胞肺癌；安罗替尼；注射用紫杉醇（白蛋白结合型）；二线治疗

英文关键词：Non-smallcelllungcancer;Anlotinib;Paclitaxelforinjection(albuminbound);Second-linetreatment

• 摘要：

• 目的 探讨安罗替尼联合注射用紫杉醇（白蛋白结合型）二线治疗晚期驱动基因阴性非小细胞肺癌(NSCLC)的效果及安全性。方法 选取2018年9月至2019年9月安徽省亳州市人民医院肿瘤内科收治的经组织学或细胞学检查确诊为Ⅳ期（晚期）驱动基因阴性NSCLC患者，采用随机数字表法分为观察组（32例）及对照组（30例）。观察组采用安罗替尼联合注射用紫杉醇（白蛋白结合型）治疗，对照组采用注射用紫杉醇（白蛋白结合型）单药治疗。21 d为1个治疗周期，比较2组治疗2个周期后疗效，治疗前后肺癌患者生存质量测定量表（FACT-L）评分，生存状况和不良反应情况。结果 观察组治疗2个周期后疾病控制率明显高于对照组［87.5%（28/32）比60.0%（18/30）］，差异有统计学意义（P=0.013）。治疗后，2组FACT-L问卷中附加的关注情况评分均低于治疗前，且观察组明显低于对照组［（8.5±2.5）分比（11.6±1.3）分］（均P＜0.05）。Log-rank生存分析结果显示，观察组6个月无进展生存率明显高于对照组，差异有统计学意义（P=0.001）。2组患者治疗后不良反应均以1～2级为主。结论 安罗替尼联合注射用紫杉醇（白蛋白结合型）二线治疗可提高NSCLC患者的疾病控制率及无进展生存率，同时安全性较好。

• Objective To investigate the therapeutic efficacy and safety of anlotinib combined with paclitaxel for injection (albumin bound) as the second-line therapy on patients with advanced driving gene negative non-small cell lung cancer (NSCLC). Methods From September 2018 to September 2019, patients with stage Ⅳ (advanced) driving gene negative NSCLC diagnosed by histology or cytology in the Department of Oncology, the People′s Hospital of Bozhou, Anhui Province were selected. They were randomly divided into observation group (32 cases) and control group (30 cases). The observation group was given anlotinib combined with paclitaxel for injection (albumin bound), while the control group was treated with paclitaxel for injection (albumin bound) alone. The short-term efficacy of 2 cycles after therapy, functional assessment of cancer therapy-lung (FACT-L) score before and after treatment, survival status and adverse reactions were compared between the two groups. Results After 2 cycles of therapy, the disease control rate of the observation group was significantly higher than that of the control group［87.5%(28/32) vs 60.0%(18/30)］(P=0.013). After treatment, the additional attention scores in FACT-L questionnaire of the two groups were lower than those before treatment, and that of the observation group was significantly lower than that of the control group［（8.5±2.5） vs （11.6±1.3）］(all P＜0.05). Log-rank survival analysis showed that the 6-month progression free survival rate of the observation group was significantly higher than that of the control group (P=0.001). The main adverse reactions of the two groups were mainly grade 1-2. Conclusion Anlotinib combined with paclitaxel for injection (albumin bound) can improve the second-line therapeutic effect on NSCLC, and enhance the disease control rate and progression free survival rate, with good safety.